Baseline patient characteristics
| . | All patients (N = 35) . |
|---|---|
| Median age (range), y | 69 (44-84) |
| Male:female | 26 (74%):9 (26%) |
| Median time from initial diagnosis (mo) | 31.8 |
| Prior therapy for MF | 30 (86%) |
| Medical therapy | 30 (86%) |
| Radiotherapy | 3 (9%) |
| Median number of prior therapies (range) | 1 (0-6) |
| ECOG performance status | |
| 0 | 10 (29%) |
| 1 | 21 (60%) |
| 2 | 2 (6%) |
| Missing | 2 (6%) |
| MF diagnosis | |
| Primary MF | 22 (63%) |
| PPV-MF | 6 (17%) |
| PET-MF | 6 (17%) |
| Other (ineligible, not MF)* | 1 (3%) |
| Baseline DIPSS risk category | |
| High | 7 (20%) |
| Intermediate-1 | 12 (34%) |
| Intermediate-2 | 13 (37%) |
| Indeterminate† | 3 (9%) |
| Baseline Lille score | |
| High risk | 10 (29%) |
| Intermediate risk | 12 (34%) |
| Low risk | 13 (37%) |
| JAK2 mutation positive | 28 (80%) |
| Hematologic parameters | |
| Hemoglobin (g/L) | |
| Median (range) | 102 (55-181) |
| Mean (SD) | 104 (23) |
| Grade 0-2 | 31 (89%) |
| Grade 3-4 | 4 (11%) |
| RBC-transfusion dependent | 10 (28.6%) |
| Platelets (×103/μL) | |
| Median (range) | 121 (15-859) |
| Mean (SD) | 186 (184) |
| Grade 0-2 | 28 (80%) |
| Grade 3-4 | 7 (20%) |
| Patients with baseline platelets | |
| <150 000/μL | 19 (54%) |
| <100 000/μL | 15 (43%) |
| < 50 000/μL | 7 (20%) |
| Leukocytes (×103/μL) | |
| Median (range) | 11.7 (1.1-89.6) |
| Mean (SD) | 17.9 (19.0) |
| Leukopenia | |
| Grade 0 | 32 (91%) |
| Grade 3 | 3 (9%) |
| Median spleen volume by MRI (range), mL | 2300 (404-7818) |
| Median spleen size by physical examination below left costal margin (range), cm | 13 (5-30) |
| Median symptom score (range) | 18 (0-44) |
| Median score for individual symptoms (range) | |
| Abdominal pain | 2 (0-10) |
| Bone pain | 0 (0-8) |
| Early satiety | 5 (0-10) |
| Fatigue (worst) | 5 (0-10) |
| Inactivity | 3 (0-10) |
| Night sweats | 1 (0-10) |
| Pruritus | 1 (0-9) |
| . | All patients (N = 35) . |
|---|---|
| Median age (range), y | 69 (44-84) |
| Male:female | 26 (74%):9 (26%) |
| Median time from initial diagnosis (mo) | 31.8 |
| Prior therapy for MF | 30 (86%) |
| Medical therapy | 30 (86%) |
| Radiotherapy | 3 (9%) |
| Median number of prior therapies (range) | 1 (0-6) |
| ECOG performance status | |
| 0 | 10 (29%) |
| 1 | 21 (60%) |
| 2 | 2 (6%) |
| Missing | 2 (6%) |
| MF diagnosis | |
| Primary MF | 22 (63%) |
| PPV-MF | 6 (17%) |
| PET-MF | 6 (17%) |
| Other (ineligible, not MF)* | 1 (3%) |
| Baseline DIPSS risk category | |
| High | 7 (20%) |
| Intermediate-1 | 12 (34%) |
| Intermediate-2 | 13 (37%) |
| Indeterminate† | 3 (9%) |
| Baseline Lille score | |
| High risk | 10 (29%) |
| Intermediate risk | 12 (34%) |
| Low risk | 13 (37%) |
| JAK2 mutation positive | 28 (80%) |
| Hematologic parameters | |
| Hemoglobin (g/L) | |
| Median (range) | 102 (55-181) |
| Mean (SD) | 104 (23) |
| Grade 0-2 | 31 (89%) |
| Grade 3-4 | 4 (11%) |
| RBC-transfusion dependent | 10 (28.6%) |
| Platelets (×103/μL) | |
| Median (range) | 121 (15-859) |
| Mean (SD) | 186 (184) |
| Grade 0-2 | 28 (80%) |
| Grade 3-4 | 7 (20%) |
| Patients with baseline platelets | |
| <150 000/μL | 19 (54%) |
| <100 000/μL | 15 (43%) |
| < 50 000/μL | 7 (20%) |
| Leukocytes (×103/μL) | |
| Median (range) | 11.7 (1.1-89.6) |
| Mean (SD) | 17.9 (19.0) |
| Leukopenia | |
| Grade 0 | 32 (91%) |
| Grade 3 | 3 (9%) |
| Median spleen volume by MRI (range), mL | 2300 (404-7818) |
| Median spleen size by physical examination below left costal margin (range), cm | 13 (5-30) |
| Median symptom score (range) | 18 (0-44) |
| Median score for individual symptoms (range) | |
| Abdominal pain | 2 (0-10) |
| Bone pain | 0 (0-8) |
| Early satiety | 5 (0-10) |
| Fatigue (worst) | 5 (0-10) |
| Inactivity | 3 (0-10) |
| Night sweats | 1 (0-10) |
| Pruritus | 1 (0-9) |